Advancements in chimeric antigen receptor-expressing T-cell therapy for glioblastoma multiforme: Literature review and future directions.
Michael GoutnikAlexandria IakovidisMegan E H StillRachel S F MoorKaitlyn MelnickSandra YanMuhammad AbbasJianping HuangAshley P GhiaseddinPublished in: Neuro-oncology advances (2024)
Glioblastoma multiforme (GBM) is an aggressive cancer that has been difficult to treat and often requires multimodal therapy consisting of surgery, radiotherapy, and chemotherapy. Chimeric antigen receptor-expressing (CAR-T) cells have been efficacious in treating hematological malignancies, resulting in several FDA-approved therapies. CAR-T cells have been more recently studied for the treatment of GBM, with some promising preclinical and clinical results. The purpose of this literature review is to highlight the commonly targeted antigens, results of clinical trials, novel modifications, and potential solutions for challenges that exist for CAR-T cells to become more widely implemented and effective in eradicating GBM.
Keyphrases
- clinical trial
- case report
- locally advanced
- papillary thyroid
- minimally invasive
- early stage
- coronary artery bypass
- cell therapy
- dendritic cells
- pain management
- cancer therapy
- radiation induced
- current status
- randomized controlled trial
- squamous cell carcinoma
- stem cells
- surgical site infection
- bone marrow
- replacement therapy
- young adults
- lymph node metastasis
- risk assessment
- drug delivery